FY2017 EPS Estimates for FibroGen, Inc Lifted by Analyst (FGEN)

FibroGen, Inc (NASDAQ:FGEN) – Equities researchers at William Blair raised their FY2017 earnings estimates for FibroGen in a report issued on Thursday. William Blair analyst A. Hsieh now forecasts that the biopharmaceutical company will earn ($1.64) per share for the year, up from their previous estimate of ($2.02). William Blair currently has a “Outperform” rating on the stock. William Blair also issued estimates for FibroGen’s Q4 2017 earnings at ($0.15) EPS, Q1 2018 earnings at ($0.51) EPS, Q2 2018 earnings at ($0.53) EPS, Q4 2018 earnings at ($0.60) EPS, FY2018 earnings at ($0.65) EPS, FY2019 earnings at $1.50 EPS and FY2020 earnings at ($1.82) EPS.

WARNING: “FY2017 EPS Estimates for FibroGen, Inc Lifted by Analyst (FGEN)” was posted by Markets Daily and is the property of of Markets Daily. If you are reading this story on another publication, it was illegally copied and republished in violation of U.S. and international copyright and trademark laws. The original version of this story can be viewed at https://www.themarketsdaily.com/2017/11/14/fy2017-eps-estimates-for-fibrogen-inc-lifted-by-analyst-fgen.html.

Several other equities research analysts have also commented on FGEN. Goldman Sachs Group, Inc. (The) lowered shares of FibroGen from a “buy” rating to a “neutral” rating and set a $31.00 price objective for the company. in a research note on Friday, July 21st. BidaskClub lowered shares of FibroGen from a “strong-buy” rating to a “buy” rating in a research note on Monday, July 31st. Stifel Nicolaus raised their price target on shares of FibroGen from $38.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday, August 8th. Jefferies Group LLC restated a “buy” rating and set a $75.00 price target on shares of FibroGen in a research note on Tuesday, August 8th. Finally, Citigroup Inc. raised their price target on shares of FibroGen from $48.00 to $65.00 and gave the stock a “top pick” rating in a research note on Tuesday, August 8th. Two investment analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $65.67.

Shares of FibroGen (NASDAQ:FGEN) opened at $46.20 on Monday. The company has a debt-to-equity ratio of 0.16, a current ratio of 10.83 and a quick ratio of 10.83. FibroGen has a one year low of $19.25 and a one year high of $60.15.

In related news, VP Pat Cotroneo sold 2,851 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $49.45, for a total value of $140,981.95. Following the completion of the transaction, the vice president now directly owns 157,405 shares of the company’s stock, valued at approximately $7,783,677.25. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Kalevi Kurkijarvi sold 2,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 17th. The stock was sold at an average price of $40.74, for a total transaction of $81,480.00. Following the completion of the transaction, the director now directly owns 30,000 shares of the company’s stock, valued at $1,222,200. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 428,118 shares of company stock valued at $22,355,896. 14.90% of the stock is owned by insiders.

Large investors have recently made changes to their positions in the business. New York State Common Retirement Fund boosted its holdings in FibroGen by 24.0% in the 2nd quarter. New York State Common Retirement Fund now owns 67,700 shares of the biopharmaceutical company’s stock valued at $2,187,000 after purchasing an additional 13,099 shares during the period. FMR LLC boosted its holdings in FibroGen by 96.9% in the 2nd quarter. FMR LLC now owns 3,335,997 shares of the biopharmaceutical company’s stock valued at $107,753,000 after purchasing an additional 1,641,423 shares during the period. Prudential Financial Inc. boosted its holdings in FibroGen by 9.6% in the 2nd quarter. Prudential Financial Inc. now owns 448,780 shares of the biopharmaceutical company’s stock valued at $14,496,000 after purchasing an additional 39,430 shares during the period. Principal Financial Group Inc. boosted its holdings in FibroGen by 0.4% in the 1st quarter. Principal Financial Group Inc. now owns 136,045 shares of the biopharmaceutical company’s stock valued at $3,354,000 after purchasing an additional 504 shares during the period. Finally, Citigroup Inc. boosted its holdings in FibroGen by 37.3% in the 2nd quarter. Citigroup Inc. now owns 40,046 shares of the biopharmaceutical company’s stock valued at $1,294,000 after purchasing an additional 10,876 shares during the period. 46.93% of the stock is owned by hedge funds and other institutional investors.

About FibroGen

FibroGen, Inc is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer.

Earnings History and Estimates for FibroGen (NASDAQ:FGEN)

Receive News & Ratings for FibroGen Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for FibroGen Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply